Article Text

Download PDFPDF

994 Impact of lymphadenectomy on survival of patients with serous advanced ovarian cancer after neoadjuvant chemotherapy: a national multicenter study
  1. V Bund1,
  2. L Lecointre1,
  3. M Velten2,
  4. L Ouldamer3,
  5. S Bendifallah4,
  6. M Koskas5,
  7. PA Bolze6,
  8. P Collinet7,
  9. G Canlorbe8,
  10. T Touboul9,
  11. C Huchon10,
  12. C Coutant11,
  13. E Faller1,
  14. T Boisramé1,
  15. J Gantzer12,
  16. M Demarchi13,
  17. JJ Baldauf1,
  18. M Ballester14,
  19. V Lavoue15 and
  20. C Akladios1
  1. 1Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  2. 2Department of Public Health, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  3. 3Department of Gynecology, Hôpital Universitaire de Tours, Tours, France
  4. 4Department of Gynaecology and Obstetrics, Hôpital Tenon, AP-HP, Paris, France
  5. 5Department of Gynecology, Hôpital Bichat, AP-HP, Paris, France
  6. 6Gynecological Surgery Service, CHU Lyon-Sud, Pierre-Bénite, Lyon, France
  7. 7Department of Gynecological Surgery, Hôpital Jeanne De Flandre, CHRU, Lille, France
  8. 8Department of Gynecologic and Breast Surgery and Oncology, Hôpital la Pitié Salpétrière, AP-HP, Paris, France
  9. 9Department of Obstetrics and Gynaecology, Centre Hospitalier Intercommunal, Créteil, France
  10. 10Department of Gynecology, Centre Hospitalier de Poissy, Poissy, France
  11. 11Department of Surgical Oncology, Georges-Francois Leclerc Cancer Center, Dijon, France
  12. 12Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, , France
  13. 13Medical Oncology Department, Centre Paul Strauss, Strasbourg, France
  14. 14Department of Gynecologic and Breast Surgery, Groupe Hospitalier Diaconesses Croix, Saint-Simon, Paris, France
  15. 15Department of Gynecologic Surgery, Hôpital Universitaire de Rennes, Rennes, France


Title: Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN).

Introduction/Background*The population of interest to this study comprised individuals with advanced-stage ovarian carcinoma who were exposed to neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). Those who had not received systematic lymphadenectomy (SL; Group 1) were compared to those who had received SL (Group 2). Outcome measures included progression-free survival (PFS), overall survival (OS), and surgical complications. (Group 1).

Methodology This was a retrospective, multicenter cohort study in nine referral centers of France between January 2000 and June 2017. OS analysis using the multivariate Cox regression model was performed. PFS and surgery-related morbidity were analyzed.

Result(s)*Of the 255 patients included, 100 were in Group 1 and 155 in Group 2. Patient majority was, on average, younger and less comorbid, with predominant R0 surgery in Group 2. Dindo–Clavien score was similar between the two groups (p = 0.15). Median OS was 26.8 months in Group 2 and 27.6 months in Group 1. SL was not statistically significant on OS (p = 0.7). Median PFS was 18.3 months in Group 2 and 16.6 months in Group 1. SL had positive impact on PFS (p = 0.005).

Abstract 994 Figure 1

Flowchart of patient selection.

Abstract 994 Figure 2

Overall survival in patients with serous ovarian carcinoma after NAC with or without lymphadenectomy.

Abstract 994 Figure 3

Progression-free survival in patients with serous ovarian carcinoma after NAC with or without lymphadenectomy.

Conclusion*Patients who had received SL (Group 2) had significantly higher PFS regardless of node-positivity status when compared to those who had not received SL

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.